ArticleEuropean journal of clinical pharmacology2015
Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case-Control Surveillance Study.
Article in European journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Pharmacogenetics of metamizole-induced agranulocytosis: a systematic review and drug regulation implications.Frontiers in pharmacology · 2025Pooled it
- Pooled it
- Dipyrone as pre-emptive measure in postoperative analgesia after tonsillectomy in children: a systematic review.Brazilian journal of otorhinolaryngologyPooled it
- Cytochrome P450 1A2 is the most important enzyme for hepatic metabolism of the metamizole metabolite 4-methylaminoantipyrine.British journal of clinical pharmacology · 2022Trial
- A clinical case and pharmacokinetic analysis of an inadvertent overdose of dipyrone (metamizole) without clinical toxicity: A case report.SAGE open medical case reports · 2026Article
- Metamizole-induced agranulocytosis from a German intensive care perspective.Frontiers in medicine · 2026Article
- Clinical Validation of Quality Indicators for the Pharmacological Management of Chronic Non-Cancer Pain in Older Adult Inpatients.Journal of pain research · 2026Article
- Learning From the Uncommon in Common Practice: A Case Report on Metamizole-Induced Agranulocytosis.Cureus · 2025Article
- [European Medicines Agency checks metamizole: stronger focus on agranulocytosis but also established use in treatment].Schmerz (Berlin, Germany) · 2025Article
- Drug-Induced Liver Injury Caused by Metamizole: Identification of a Characteristic Injury Pattern.Liver international : official journal of the International Association for the Study of the Liver · 2025Observational
- Methotrexate - Safe Backbone for the Treatment of Rheumatoid Arthritis.Current rheumatology reviews · 2025Review
- A probable case of metamizole-induced neutropaenia presenting 10 days after drug discontinuation.SAGE open medical case reports · 2025Article
- Developing Quality Indicators for the Pharmacological Management of Chronic Non-Cancer Pain in Older Adult Inpatients: A RAND/UCLA Delphi Study.Journal of pain research · 2025Article
- Risk of agranulocytosis with metamizole in comparison with alternative medications based on health records in Spain.European journal of clinical pharmacology · 2024Article
- Isolated Severe Neutropenia in Adults, Evaluation of Underlying Causes and Outcomes, Real-World Data Collected over a 5-Year Period in a Tertiary Referral Hospital.Medicina (Kaunas, Lithuania) · 2024Article
- Metamizole-induced agranulocytosis (MIA): a mini review.Molecular and cellular pediatrics · 2023Review
- Case Report: Simultaneously Induced Neutropenia and Hemolysis After a Single Metamizole Dose.Drugs in R&D · 2023Article
- Article
- Self-Medication in Rural Northeastern Romania: Patients' Attitudes and Habits.International journal of environmental research and public health · 2022Article
- Metamizole Use in Children: Analysis of Drug Utilisation and Adverse Drug Reactions at a German University Hospital between 2015 and 2020.Paediatric drugs · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTreatment with metamizole (dipyrone) has steadily increased in Germany over the last decade. The consequences of this increase for metamizole-induced agranulocytosis (MIA) are unclear. The present study addressed this topic using data from the Berlin Case-Control Surveillance Study.
methodsAdult patients (≥18 years of age) with acute nonchemotherapy-induced agranulocytosis were identified by active surveillance in all 51 Berlin hospitals between 2000 and 2010. Cases related to metamizole were ascertained applying the drug causality criteria of the World Health Organization. The incidence rate of MIA was calculated and standardised by age and sex based on the German standard population in 2010.
resultsTwenty-six MIA cases out of 88 (30 %) patients with validated agranulocytosis were ascertained. The incidence of MIA was 0.96 (95 % confidence interval (CI) 0.95-0.97) cases per million per year. The median age of MIA cases was 50 years (quartile (Q)1 31 years; Q3 68 years) and 19 (73 %) of them were women. In 17 (65 %) cases, neutrophil granulocytes dropped below the value of 0.1 × 10(9) cells/L with three patients suffering from sepsis. Headache and postoperative pain were the most frequent indications for metamizole in outpatients (n = 16) and inpatients (n = 10), respectively. The median treatment duration was 6 days (Q1 4 days; Q3 19 days).
conclusionsMIA persists as a severe condition in current pharmacotherapy. The continuous increase of metamizole applications should be critically assessed, especially in regard to indications in the outpatient setting and with respect to metamizole treatment duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.